Genetic testing has become an increasingly important tool in the diagnosis, risk assessment, and clinical management of neurodegenerative diseases[1]. With the identification of hundreds of genes implicated in conditions ranging from Alzheimer's Disease to amyotrophic lateral sclerosis, genetic testing now plays a critical role in confirming diagnoses, identifying presymptomatic carriers, guiding family planning decisions, and — increasingly — determining eligibility for targeted therapies such as tofersen for SOD1-mutant ALS and anti-amyloid antibodies for APOE ε4 carriers[2]. [1:1]
Single-gene testing targets a specific gene when a particular condition is strongly suspected based on clinical presentation and family history. This approach is most appropriate for: [2:1]
Multigene panels simultaneously analyze 20–500+ genes associated with a particular disease category. Current panels include: [3]
These panels offer a balance between breadth and cost-effectiveness, making them suitable for patients with heterogeneous clinical presentations[3:1]. [4]
WES and WGS provide the most comprehensive genetic analysis, covering all protein-coding regions (WES) or the entire genome including non-coding variants (WGS). These approaches are particularly useful for: [5]
WGS has become increasingly cost-effective, with the cost per genome dropping below $200 in 2025, making it accessible for clinical use. Recent studies demonstrate that WGS can identify pathogenic variants in 15–25% of previously undiagnosed neurodegenerative cases[4:1]. [6]
Several neurodegenerative diseases are caused by nucleotide repeat expansions that require specialized testing methods: [7]
| Disease | Gene | Repeat | Pathogenic Threshold |
|---|---|---|---|
| Huntington's Disease | HTT | CAG | ≥36 repeats |
| FTD/ALS | C9orf72 | GGGGCC | ≥30 repeats |
| SCA1 | ATXN1 | CAG | ≥39 repeats |
| SCA2 | ATXN2 | CAG | ≥33 repeats |
| SCA3 | ATXN3 | CAG | ≥55 repeats |
| Friedreich's Ataxia | FXN | GAA | ≥66 repeats |
| Myotonic dystrophy | DMPK | CTG | ≥50 repeats |
| FXTAS | FMR1 | CGG | 55–200 (premutation) |
| DRPLA | ATN1 | CAG | ≥48 repeats |
Standard next-generation sequencing often misses large repeat expansions, requiring specialized methods such as repeat-primed PCR, Southern blotting, or long-read sequencing technologies (PacBio, Oxford Nanopore)[5:1].
APOE genotyping plays a unique role in neurodegenerative disease risk assessment, particularly for Alzheimer's Disease. The APOE gene has three common alleles (ε2, ε3, ε4), with ε4 being a major risk factor for late-onset AD[6:1].
Genetic counseling is essential both before and after genetic testing for neurodegenerative diseases. Pre-test counseling helps patients understand the implications of potential results, including the psychological impact, insurance considerations, and family implications. Post-test counseling aids in result interpretation and planning for the future[7:1].
GeneTests — Medical genetics information resource
PDGene Database — Parkinson's Disease gene database
ALS Online Genetics Database — ALS gene variant database
The study of Genetic Testing For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Goldman JS, et al. Genetic testing and genetic counseling for Alzheimer's Disease. 2023. ↩︎ ↩︎
Apostolova LG, et al. Genetic testing and genetic counseling for Alzheimer's Disease: Practice trends and future directions. 2024. ↩︎ ↩︎
Koriath C, et al. Genetic testing in dementia: A practical guide. 2021. ↩︎ ↩︎
Bis-Brewer J, et al. Whole-genome sequencing in neurodegenerative diseases. 2024. ↩︎ ↩︎
Rohilla S, et al. Repeat expansion detection in neurodegenerative diseases. 2019. ↩︎ ↩︎
Bellenguez C, et al. APOE and Alzheimer's disease: Genetics, pathophysiology and therapeutic implications. 2022. ↩︎ ↩︎
Code P, et al. Genetic counseling for neurodegenerative diseases: Current practices and future directions. 2023. ↩︎ ↩︎